Imipenem - Cilastatin versus Sulbactam - Cefoperazone plus Amikacin in the Initial Treatment of Febrile Neutropenic Cancer Patients
Ozgur Ozyilkan, Ulku Yalcintas, Sezgin Baskan
Korean J Intern Med. 1999;14(2):15-19. Published online 1999 Jul 1 DOI: https://doi.org/10.3904/kjim.1999.14.2.15
Citations to this article as recorded by 
Inappropriate initial antimicrobial therapy for hematological malignancies patients with Gram-negative bloodstream infections
Yishu Tang, Xinyu Wu, Qian Cheng, Xin Li
Infection.2020; 48(1): 109. CrossRef
Efficacy and safety of cefoperazone-sulbactam in empiric therapy for febrile neutropenia
Shao-Huan Lan, Shen-Peng Chang, Chih-Cheng Lai, Li-Chin Lu, Hung-Jen Tang
Medicine.2020; 99(8): e19321. CrossRef
Amikacin and cefoperazone/sulbactam alone or in combination against carbapenem-resistant Pseudomonas aeruginosa
Yun Cai, Deqing Yang, Jin Wang, Rui Wang
Diagnostic Microbiology and Infectious Disease.2018; 91(2): 186. CrossRef
Piperacillin/tazobactam vs. cefoperazone/sulbactam in adult low-risk febrile neutropenia cases
O. R. Sipahi, B. Arda, A. Nazli-Zeka, H. Pullukcu, M. Tasbakan, T. Yamazhan, S. Ozkoren-Calik, H. Sipahi, S. Ulusoy
International Journal of Clinical Practice.2014; 68(2): 230. CrossRef
Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia
Mical Paul, Yaakov Dickstein, Agata Schlesinger, Simona Grozinsky-Glasberg, Karla Soares-Weiser, Leonard Leibovici
Cochrane Database of Systematic Reviews.2013;[Epub] CrossRef
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
Alison G. Freifeld, Eric J. Bow, Kent A. Sepkowitz, Michael J. Boeckh, James I. Ito, Craig A. Mullen, Issam I. Raad, Kenneth V. Rolston, Jo-Anne H. Young, John R. Wingard
Clinical Infectious Diseases.2011; 52(4): e56. CrossRef
Executive Summary: Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
Alison G. Freifeld, Eric J. Bow, Kent A. Sepkowitz, Michael J. Boeckh, James I. Ito, Craig A. Mullen, Issam I. Raad, Kenneth V. Rolston, Jo-Anne H. Young, John R. Wingard
Clinical Infectious Diseases.2011; 52(4): 427. CrossRef
Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: A randomized, prospective study
Nabil Ahmed, Hadir A. El‐Mahallawy, Ibrahim A. Ahmed, Shimaa Nassif, Aamal El‐Beshlawy, Alaa El‐Haddad
Pediatric Blood & Cancer.2007; 49(6): 786. CrossRef
Evaluation of Imipenem 1.5 g Daily in Febrile Patients with Short Duration Neutropenia After Chemotherapy for Non-leukemic Hematologic Malignancies and Solid Tumors: Personal Experience and Review of the Literature
E. Jourdan, C. Defez, D. Topart, B. Richard, H. Bellabas, P. Fabbro-Peray, J. Jourdan, A. Sotto
Leukemia & Lymphoma.2003; 44(4): 619. CrossRef
2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer
Walter T. Hughes, Donald Armstrong, Gerald P. Bodey, Eric J. Bow, Arthur E. Brown, Thierry Calandra, Ronald Feld, Philip A. Pizzo, Kenneth V. I. Rolston, Jerry L. Shenep, Lowell S. Young
Clinical Infectious Diseases.2002; 34(6): 730. CrossRef
Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis
Paolo Furno, Giampaolo Bucaneve, Albano Del Favero
The Lancet Infectious Diseases.2002; 2(4): 231. CrossRef